Cytek Biosciences (CTKB) Non-Current Deffered Revenue (2020 - 2026)

Cytek Biosciences (CTKB) has 7 years of Non-Current Deffered Revenue data on file, last reported at $17.7 million in Q1 2026.

• Quarterly Non-Current Deffered Revenue rose 12.44% year-over-year to $17.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.7 million (up 12.44% YoY) and the FY2025 annual result came in at $18.3 million, up 13.92% from the prior year.
• Non-Current Deffered Revenue fell to $17.7 million in Q1 2026, from $18.3 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $18.3 million in Q4 2025 to a low of $7.2 million in Q1 2022.
• A 5-year average of $14.5 million and a median of $15.1 million in 2023 frame the typical range for Non-Current Deffered Revenue.
• Annual changes were most pronounced in 2023 — Non-Current Deffered Revenue jumped 80.75% — and 2024, when it slipped 12.4%.
• Tracing CTKB's Non-Current Deffered Revenue over 5 years: stood at $13.1 million in 2022, then increased by 15.3% to $15.1 million in 2023, then increased by 6.38% to $16.1 million in 2024, then gained by 13.92% to $18.3 million in 2025, then decreased by 3.64% to $17.7 million in 2026.
• The last three Non-Current Deffered Revenue figures came in at $17.7 million (Q1 2026), $18.3 million (Q4 2025), and $16.3 million (Q3 2025), per Business Quant data.